secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K/A
Filed at:   2026-06-22T20:25:36+00:00
Accession:  0001193125-26-277570
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health explores strategic alternatives for crofelemer rare disease program
--------------------------------------------------------------------------------

- Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.
- Timing aligns with planned NDA filing for crofelemer in rare intestinal failure diseases (MVID, SBS-IF).
- Proof-of-concept trial in MVID/SBS-IF showed up to 37% reduction in parenteral support.
- Market research estimates global nutritional support for MVID at ~$1.1B in 2026, rising to ~$1.5B in 2033.
- CEO Lisa Conte to present updates at Life Sciences Virtual Investor Forum on June 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526277570/0001193125-26-277570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526277570/d121487d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer